ANALYSIS OF TUBERCULOSIS TREATMENT SUITABILITY AND THE DRUG SUPERVISOR’S ROLE IN A COMMUNITY HEALTH CENTER IN PADEMANGAN SUBDISTRICT, NORTH JAKARTA
DOI:
https://doi.org/10.22159/ijap.2019.v11s1.030Keywords:
Fixed-dose combination, Drug supervisor, TuberculosisAbstract
Objective: Appropriate tuberculosis (TB) treatment guidelines are one of the many factors that influence the success of TB treatment. The patient’s
drug supervisor is a functional role that is part of the directly observed treatment short course, a program to support the success of TB treatment.
The aim of this study was to analyze the TB treatment suitability in a community health center and the benefit of treatment compliance supervision
by the patient’s designated drug supervisor.
Methods: We conducted a cross-sectional study in the Community Health Center of Pademangan subdistrict, North Jakarta, involving 205 subjects to
analyze appropriate fixed-dose combination (FDC) anti-TB drug administration and an experimental study involving 23 control group TB patients and
23 intervention group TB patients to assess the benefit of supervision by each patient’s drug supervisor.
Results: The association of FDC anti-TB drug side effects with the success of TB treatment was not statistically significant (p=0.173). There was
an increase in drug supervisor knowledge of 8.6% in the intervention group and 13% in the control group. There was no statistically significant
association between the knowledge of the drug supervisor and the 2nd month (p=0.575) and the 6th month of sputum treatment.
Conclusion: Minor side effects of FDC anti-TB drug did not affect the success of TB treatment; therefore, treatment was continued if these adverse
events occurred. There were no correlations between the drug supervisor knowledge level with medication compliance or with sputum conversion
(months 2 and 6).
Downloads
References
et al. Global Plan End to TB: The Paradigm Shift 2016-2020. Report
Stop TB Partnership; 2015. p. 19-23.
2. Anderson L, Dean A, Falzon D, Floyd K, Baena I, Gilpin C, et al. Global
Tuberculosis Report 2015. 20th ed. Geneva: World Health Organization;
2015. p. 1-5.
3. Pletzer K, Louw J. Prevalence and factors associated with tuberculosis
treatment outcome among hazardous or harmful alcohol users in public
primary health care in South Africa. Afr Health Sci 2014;14:157-66.
4. World Health Organization. WHO Global Tuberculosis Report 2015.
Global Tuberculosis Report 2015. 20th ed. Dalam: World Health
Organization; 2015. p. 1-2.
5. DKI Jakarta Public Health Office. Health Profile of DKI JakartaProvince. Jakarta: DKI Jakarta Public Health Office; 2012. p.
26-276. Pademangan Community Empowerment Institute.
Pademangan Health Center North Jakarta; 2010. p. 85-8.
6. Pademangan Community Empowerment Institute. Pademangan Health
Center North Jakarta; 2010. p. 85-7.
7. Ministry of Health Republic of Indonesia. Current Situation Fact Sheet
for Tuberculosis Control Progress. Vol. 2015; 2015. p. 1-5.
8. Isbaniyah F, Thabrani Z, Soepandi ZS, Burhan E, Reviono, Soedarsono, et
al. Tuberculosis Diagnostic and Management
Guidelines in Indonesia. Jakarta: Indonesian Respiratory Doctors
Association; 2011. p. 1-66.
9. Rian S. Effect of Anti-Tuberculosis Drug Side Effects on the Occurrence
of Defaults in Islamic Hospitals in Pondok Kopi Jakarta East January
2008-2010 [Thesis]. University of Indonesia Faculty of Public Health;
2010. p. 8-29.